Truist Securities Maintains Buy on Nurix Therapeutics, Raises Price Target to $34
RBC Capital Maintains Outperform on Nurix Therapeutics, Raises Price Target to $33
Stifel Maintains Buy on Nurix Therapeutics, Raises Price Target to $40
BTIG Reiterates Buy on Nurix Therapeutics, Maintains $32 Price Target
Needham Reiterates Buy on Nurix Therapeutics, Maintains $34 Price Target
HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Raises Price Target to $34
Nurix Therapeutics Q2 EPS $(0.81) Misses $(0.74) Estimate, Sales $9.043M Miss $16.170M Estimate
Baird Maintains Outperform on Nurix Therapeutics, Raises Price Target to $33
Nurix Therapeutics Deal With Roche Is Worth Betting On
Nurix to Present Updated CLL Drug Data at EHA 2026, Says Bexobrutideg Shows Durable Responses in CLL Trial
HC Wainwright & Co. Reiterates Buy on Nurix Therapeutics, Maintains $32 Price Target
Truist Securities Maintains Buy on Nurix Therapeutics, Raises Price Target to $32
BTIG Maintains Buy on Nurix Therapeutics, Raises Price Target to $32
Nurix Therapeutics, Inc. (NRIX) Discusses Strategic Collaboration for Development and Commercialization of Bexobrutideg for BTK-Mediated Diseases - Slideshow
Nurix Therapeutics, Inc. (NRIX) Discusses Strategic Collaboration for Development and Commercialization of Bexobrutideg for BTK-Mediated Diseases Transcript
Jefferies Maintains Buy on Nurix Therapeutics, Raises Price Target to $45
Needham Maintains Buy on Nurix Therapeutics, Raises Price Target to $34
Nurix Therapeutics, Inc. (NRIX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
BTIG Reiterates Buy on Nurix Therapeutics, Maintains $30 Price Target
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
